AIM2 (Absent in Melanoma 2) is a critical cytosolic DNA sensor that plays essential roles in innate immunity and has emerged as a significant player in neurodegenerative disease pathogenesis[@deyoung1992][@choubey2012]. The AIM2 gene encodes a protein belonging to the HIN-200 (hematopoietic interferon-inducible nuclear proteins with 200 amino acid repeats) family, which functions as a pattern recognition receptor for double-stranded DNA (dsDNA) in the cytoplasm[@burchfield2019].
The AIM2 inflammasome represents a key component of the innate immune system, detecting foreign and host-derived DNA to trigger inflammatory responses. While this function is crucial for defense against pathogens and cellular homeostasis, dysregulated AIM2 inflammasome activation has been increasingly recognized as a contributor to chronic neuroinflammation and neuronal loss in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and multiple sclerosis (MS)[@duan2019][@duan2021][@wu2020].
| Property |
Value |
| Gene Symbol |
AIM2 |
| Gene Name |
Absent in Melanoma 2 |
| Aliases |
AIM2, PYHIN4 |
| Chromosomal Location |
6q25.1 |
| NCBI Gene ID |
199 |
| UniProt ID |
Q9UMG1 |
| Ensembl ID |
ENSG00000163568 |
| Gene Type |
Protein-coding |
| Protein Family |
HIN-200 (PYHIN) family |
¶ Protein Structure and Function
¶ Domain Architecture
The AIM2 protein contains two functionally distinct domains:
- HIN domain (C-terminal): A ~200 amino acid DNA-binding domain that directly binds double-stranded DNA through electrostatic interactions with the phosphate backbone
- Pyrin domain (N-terminal): A ~90 amino acid death domain that mediates protein-protein interactions with the adaptor protein ASC
AIM2 functions as a pattern recognition receptor (PRR) for cytosolic DNA through the following mechanism[@fernandes-alnemri2020]:
¶ DNA Sensing and Inflammasome Assembly
- DNA binding: The HIN domain binds to dsDNA of bacterial, viral, or host origin in the cytoplasm
- Oligomerization: Upon DNA binding, AIM2 undergoes oligomerization to form a signaling platform
- ASC recruitment: The pyrin domain recruits the adaptor protein ASC (PYCARD) through pyrin-pyrin domain interactions
- Caspase-1 activation: ASC recruits pro-caspase-1, leading to its autocatalytic activation
- Inflammasome formation: The assembled complex constitutes the AIM2 inflammasome
- IL-1β/IL-18 processing: Active caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active forms
- Pyroptosis: Gasdermin D cleavage leads to pyroptotic cell death
- Interferon response: AIM2 can also trigger IFN-β production through STING-independent pathways
- Inflammatory cascade: Release of IL-1β and IL-18 amplifies neuroinflammation
| Pathway |
Effect |
Relevance to Neurodegeneration |
| Caspase-1 |
Inflammasome activation |
Pro-inflammatory cytokine release |
| IL-1β/IL-18 |
Pyroptosis, inflammation |
Chronic neuroinflammation |
| Gasdermin D |
Pore formation |
Cell death |
| NF-κB |
Gene activation |
Pro-inflammatory response |
| MAPK |
Stress signaling |
Contributes to dysfunction |
AIM2 is expressed in various tissues:
- Brain: Neurons, astrocytes, microglia, oligodendrocytes
- Immune system: Macrophages, dendritic cells, lymphocytes
- Other tissues: Heart, lung, spleen, liver, kidney
In the central nervous system[@hao2019]:
- Microglia: High expression, particularly in activated states
- Astrocytes: Moderate expression
- Neurons: Lower basal expression, upregulated under stress
- Oligodendrocytes: Present at lower levels
- Hippocampus: High expression in CA1-CA3 and dentate gyrus
- Cortex: Moderate expression across cortical layers
- Cerebellum: Lower expression
- Substantia nigra: Present in dopaminergic neurons
AIM2 inflammasome activation significantly contributes to AD pathogenesis[@xia2020]:
- Aβ accumulation triggers AIM2 inflammasome activation
- AIM2 activation enhances production of pro-inflammatory cytokines
- Inflammasome-mediated inflammation promotes further Aβ accumulation
- Creates a vicious cycle of inflammation and pathology
- AIM2 inflammasome activation promotes tau hyperphosphorylation
- Inflammatory cytokines contribute to tau pathology spread
- AIM2 deficiency reduces tau pathology in model systems[@jiang2021]
- Links neuroinflammation to protein aggregation
- Chronic microglial AIM2 activation drives neuroinflammation
- IL-1β release contributes to synaptic dysfunction
- Promotes microglial M1 (pro-inflammatory) phenotype
- Impairs clearance mechanisms
- AIM2 inflammasome activation affects synaptic plasticity
- IL-1β-mediated signaling disrupts LTP
- Contributes to cognitive decline
- Exacerbates memory deficits
AIM2 plays a critical role in PD progression[@chen2019]:
- AIM2 inflammasome is activated by alpha-synuclein aggregates
- Inflammasome activation promotes α-synuclein propagation
- Creates feed-forward loop between aggregation and inflammation
- Contributes to dopaminergic neuron loss
- DNA damage in dopaminergic neurons activates AIM2
- Mitochondrial stress triggers inflammasome assembly
- Contributes to energy failure in PD
- Links oxidative stress to inflammation
- Microglial AIM2 activation in substantia nigra
- Enhanced dopaminergic neuron loss
- Increased pro-inflammatory cytokine production
- Promotes disease progression
- AIM2 inhibitors may protect dopaminergic neurons
- Reducing inflammasome activation may slow progression
- Combination with other targets shows promise
AIM2 inflammasome contributes to HD pathogenesis[@kopalli2023]:
- Mutant huntingtin (mHtt) triggers AIM2 activation
- DNA damage from mHtt activates the inflammasome
- Contributes to neuronal dysfunction and loss
- AIM2 deficiency improves neuronal function
- Chronic AIM2 activation in HD models
- Elevated IL-1β in the brain
- Contributes to disease progression
- Therapeutic targeting shows benefit
- AIM2 knockout extends lifespan in HD models
- Reduces neuronal loss
- Improves motor function
- Represents promising target
- C9orf72 repeat expansions may affect AIM2-mediated responses
- Inflammasome activation in motor neurons
- Contributes to neuroinflammation
- Links innate immunity to motor neuron disease
AIM2 inflammasome activation has been reported in FTD[@liu2021]:
- Elevated AIM2 expression in FTD brain
- Contributes to neuroinflammation
- May interact with tau pathology
- Potential therapeutic target
AIM2 plays a complex role in MS[@wu2018]:
- Virus-induced AIM2 activation may trigger disease
- Inflammasome in demyelination
- Potential for both pathogenic and protective effects
- Context-dependent functions
Targeting AIM2 inflammasome represents a promising therapeutic strategy[@robert2019]:
- Direct AIM2 inhibitors under development
- Targeting DNA binding or oligomerization
- Preclinical studies show promise
- Challenges with brain penetration
- Caspase-1 inhibitors: Block inflammasome effectors
- IL-1β antagonists: Neutralize inflammatory cytokines
- Gasdermin D inhibitors: Prevent pyroptosis
- Targeting multiple points in the pathway
- Combined with disease-modifying therapies
- Personalized approaches based on patient characteristics
- AIM2 expression in peripheral blood cells
- Cerebrospinal fluid IL-1β/IL-18 levels
- Imaging markers of neuroinflammation
¶ Interacting Partners and Pathway Interactions
| Protein/Pathway |
Interaction |
Functional Consequence |
| ASC (PYCARD) |
Pyrin domain interaction |
Inflammasome assembly |
| Caspase-1 |
Recruitment and activation |
Cytokine processing |
| Pro-IL-1β |
Substrate |
Inflammatory cytokine production |
| Pro-IL-18 |
Substrate |
Interferon-γ stimulation |
| Gasdermin D |
Cleavage substrate |
Pyroptosis induction |
| DNA |
Binding via HIN domain |
Activation trigger |
| STING |
Parallel pathway |
Type I IFN response |
- AIM2 knockout mice: Available for mechanistic studies
- Conditional knockouts: For cell-type-specific deletion
- Transgenic models: For overexpression studies
- Disease models: AD, PD, HD, ALS models
- In vitro: Primary neurons, astrocytes, microglia
- iPSC-derived: Patient-specific cells
- Organoid models: Brain organoids for disease modeling
- Inhibitors: Various AIM2 inflammasome inhibitors
- Activators: DNA-based AIM2 agonists
- Detection: Antibodies for AIM2, ASC, caspase-1
¶ Research Challenges and Future Directions
- Understanding cell-type-specific AIM2 functions
- Developing brain-penetrant inhibitors
- Determining disease-stage specific effects
- Translating preclinical findings to clinical applications
- Single-cell analysis: Understanding AIM2 in specific cell types
- Epigenetic regulation: AIM2 expression control
- Post-translational modifications: Regulation of AIM2 activity
- Biomarker development: Patient stratification
- Selective AIM2 inhibitors with brain penetration
- Understanding of AIM2's dual roles (protective vs. pathogenic)
- Optimal timing for intervention
- Combination therapy strategies
- DeYoung KL et al, Cloning and characterization of AIM2 (1992)
- Choubey D et al, Interferon-inducible p200-family proteins in innate immunity (2012)
- Burchfield JG et al, AIM2 in health and disease (2019)
- Duan Y et al, Aberrant AIM2 inflammasome activation in virus-infected brain (2019)
- Duan Y et al, Role of the AIM2 inflammasome in neurodegenerative diseases (2021)
- Wu PJ et al, AIM2 in neurodegenerative diseases (2020)
- Chen Y et al, Activation of AIM2 inflammasome enhances alpha-synuclein pathology (2019)
- Xia P et al, DNA sensor AIM2 inflammasome in Alzheimer's disease (2020)
- Hao HP et al, AIM2 deficiency in mouse brain results in neuronal loss (2019)
- Kopalli SR et al, AIM2 deficiency extends lifespan in Huntington disease model (2023)
- Liu H et al, AIM2 inflammasome activation in frontotemporal dementia (2021)
- Wu H et al, AIM2 inflammasome in a murine model of multiple sclerosis (2018)
- Fernandes-Alnemri T et al, AIM2 activates the inflammasome and cell death (2020)
- Robert K et al, Therapeutic potential of targeting AIM2 inflammasome (2019)
- Morante J et al, Inflammasome activation in neurodegenerative diseases (2022)
- Jiang L et al, AIM2 inflammasome in tauopathy (2021)
- Wang B et al, AIM2 inflammasome in sepsis-associated encephalopathy (2022)
- Zhang L et al, DNA damage and AIM2 inflammasome in neurodegeneration (2023)
- Chen Q et al, Microglial AIM2 inflammasome in neurodegeneration (2022)
- Zhao C et al, AIM2 inflammasome in age-related neurodegeneration (2021)
- Li H et al, Targeting AIM2 inflammasome for neurodegenerative disease treatment (2023)
- Patel S et al, AIM2-like receptors: sensors of cytosolic DNA (2022)